Followers | 229 |
Posts | 14582 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Thursday, September 03, 2020 2:39:01 PM
You may find this recent guidance from the FDA helpful if you are concerned about possible pathways forward should the need to use historical comparisons arise.
https://www.fda.gov/media/133660/download
Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry
While we won't know until the data is unblinded how the treatment arm compared with the control arm for both PFS and OS, a pathway towards approval is still stronger than you might think, especially if you are basing your assumptions on older, more dated (IMO) paradigms.
Your concerns have been discussed on almost a daily basis here on this board for the past 5 years. Many of us have a lot riding on this, and so our DD has been pretty thorough on this topic. And here we all are, still.
There is a post of mine at the top in the sticky section where I offer up some possible pathways that you may (or may not) find helpful. It's worth reading, whether you agree or disagree with my assessments as it will give you further insights.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM